ArticleDrug delivery and translational research2025
Exosomes derived from bone marrow mesenchymal stem cells alleviate lung ischemia-reperfusion injury in rats through miRNA-335/ SIRT3 pathway.
Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung ischemia-reperfusion injury (IRI) is a clinically challenging problem. Exosomes (EXOs) derived from bone marrow mesenchymal stem cells (BMSC-EXOs) can alleviate multiple organs IRI, but few reports on lung IRI. MiRNA-335 is a kind of miRNA in EXOs, which was also shown protective effects on lung IRI. This study hypothesizes that BMSC-EXOs might alleviate lung IRI through miRNA-335, and further to explore its mechanism. The Sprague-Dawley male rats were divided into sham, IRI, phosphate buffer saline (PBS), and EXO groups (n = 6). In the sham group, rats were underwent anesthesia without IRI model establishment. In the IRI, PBS, and EXO groups, rats were established lung IRI model and with no treatment, 30 µl PBS, or 20 µg EXOs (in 30 µl PBS), respectively. The miRNA-335 inhibitor and miRNA-335 mimic processed EXOs were also given to observe the effects of miRNA-335. The oxidative index, lung static compliance, inflammation response, oxidative stress injury, apoptosis, and mitochondrial were observed. The expression of miRNA-335 and silent matching type information regulation 2 homolog 3 (SIRT3) were also detected. The oxidative index, lung static compliance, inflammation response, oxidative stress injury, apoptosis, and mitochondrial injury were significantly deteriorated in the IRI group compared with those in the sham group, while those indicators have significantly improved in the EXO group, and the miRNA-335 and SIRT3 expressions increased (P < 0.05). And the miRNA-335 inhibitor processed EXOs suppressed the SIRT3 expression significantly, but the miRNA-335 mimic processed EXOs enhanced the SIRT3 expression significantly (P < 0.05). In conclusion, BMSC-EXOs maintained mitochondrial structural stability, and alleviated rat lung IRI by inhibiting lung inflammation, oxidative stress injury, and apoptosis, improved lung oxygenation capacity and static compliance, which might be achieved through the miRNA335/SIRT3 pathway.
Indexed as
Identifiers
40180761What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.